Intellia Therapeutics downgraded by Goldman with a new price target
$NTLA
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Goldman downgraded Intellia Therapeutics from Buy to Neutral and set a new price target of $32.00 from $136.00 previously